Previous Close | 39.19 |
1-Year Change | -17.16% |
6-Months Change | 0.28% |
3-Months Change | -16.72% |
Moving Avg (50d) | 40.652 |
Moving Avg (200d) | 43.558 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 5.72B |
Beta (3-Years) | 0.79 |
Revenue Growth (ttm) | 29% |
Net Profit Margin (ttm) | -44.96% |
Return On Assets (ttm) | -13.59% |
EPS (ttm) | -2.52 |
PE Ratio (ttm) | -15.55 |
Dividend Yield | % |
Asset Description: | Ionis Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-03 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
39.974 | 41.149 | 41.933 | 43.109 | 45.068 | 47.028 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx... Wikipedia